Glendon E. French III Sells 2,326 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 2,326 shares of Pulmonx stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now directly owns 1,069,648 shares in the company, valued at approximately $6,984,801.44. This represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pulmonx Trading Down 2.1 %

NASDAQ:LUNG opened at $6.06 on Thursday. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $14.84. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $239.30 million, a price-to-earnings ratio of -4.12 and a beta of 0.66. The firm has a fifty day simple moving average of $6.43 and a two-hundred day simple moving average of $6.88.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. The company had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. During the same period last year, the business posted ($0.39) EPS. Analysts expect that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on LUNG shares. Citigroup restated a “neutral” rating and issued a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Stifel Nicolaus cut their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Wells Fargo & Company lowered their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors have recently modified their holdings of LUNG. 272 Capital LP acquired a new stake in Pulmonx in the 3rd quarter valued at $25,000. nVerses Capital LLC bought a new stake in shares of Pulmonx during the third quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Pulmonx in the 2nd quarter worth about $37,000. Hsbc Holdings PLC bought a new position in Pulmonx in the 2nd quarter valued at about $93,000. Finally, SG Americas Securities LLC acquired a new position in Pulmonx during the 3rd quarter valued at about $102,000. 91.04% of the stock is owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.